Auszug
Die Möglichkeiten einer systemischen Therapie maligner Erkrankungen - außerhalb der zytostatischen Chemotherapie - sind in den letzten Jahren deutlich erweitert worden. Dazu haben insbesondere neue Erkenntnisse zur molekularen Pathogenese von Tumorerkrankungen beigetragen. Von besonderem Interesse sind Strategien, die in Prozesse der tumorassoziierten Neoangiogenese oder der neoplastischen Wachstumsregulation eingreifen.
Chapter PDF
Similar content being viewed by others
Literatur
Literatur zu Kap. 6.1
Amato RJ (2003) Thalidomide therapy for renal cell carcinoma. Crit Rev Oncol Hematol 46: 59–65
Amato RJ (2005) Renal cell carcinoma: a review of novel single-agent therapeutics and combination regimens Ann Oncol 16: 7–15
Amato RJ, Schell J, Thompson N et al. (2003) Phase II study of thalido-mide + interleukin-2 in patients with metastatic renal cell carci-noma. Proc Am Soc Clin Oncol 22: Abstract 1556
Assikis VJ, Daliani D, Magliaro L et al. (2003) Phase II study of an autolo-gous tumor derived heat shock protein-peptide complex vaccine (HSSPC-96) for patients with metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 22: Abstract 1552)
Atkins MB, Hidalgo M, Stadler W et al. (2002) A randomized double-blind phase 2 study of intravenous CCI-779 administered weekly to patients with advanced renal cell carcinoma. Proc Am Soc Clin Onco 21: Abstract 36
Bander NH, Nanus DM, Milowsky MI et al. (2003) Phase I radioimmu-notherapy trial of humanized monoclonal antibody J591 against the extracellular domain of prostate specific membrane antigen radiolabeled with 177 leutetium in advanced prostate cancer. Proc Am Soc Clin Oncol 22: Abstract 1612
Berry W, Eisenberger M (2005) Achieving goals in hormone-refractory prostate cancer with chemotherapy. The Oncologist 10: 30–39
Chow NH, Chan SH, Tzai TS et al. (2001) Expression profiles of erbb family receptors and prognosis in primary transitional cell carci-noma of the urinary bladder. Clin Cancer Res 7: 1957–1962
Dahut WL, Gulley JL, Arlen PM et al. (2004) Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 22: 2532–2539
Davis NB, Taber DA, Ansari RH et al. (2003) A phase II trial of PS-341 in patients with renal cell cancer. Proc Am Soc Clin Oncol 22: Abstract 1551
Dawson NA, Guo N, Zak R et al. (2003) A phase II trial of ZD1839 in stage iv and recurrent renal cell carcinoma. Proc Am Soc Clin Oncol 39: Abstract 1623
Di Paola RS, Plante M, Kaufman H et al. (2006) A phase I trial of pox vaccines (PROSTAVAC-V) with ICAM-1: B7. 1 and LFA-3 co-stimula-tory molecules (TRICOM) in patients with prostate cancer. J Transl Med 4: 1–7
Drucker BJ, Schwartz L, Bacik J et al. (2003) Phase II trial of PS-341 shows response in patients with advanced renal cell carcinoma. Proc Am Soc Clin Oncol 22: Abstract 1550
Escudier B, Szczylik C, Eisen T et al. (2005) Randomized phase III trial of the Raf kinase and vegfr inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma. Proc Am Soc Clin Oncol 41: Abstract 4510
George D, Michaelson D, Oh WK et al. (2003) Phase I study of PTK787/ ZK222584 in metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 22: Abtract 1548
Gnarra JR, Tory K, Wenig Y et al. (1994) Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7: 85–90
Gnarra J R, Zhou S, Merrill MJ et al. (1996) Post-transcriptional regula-tion of vascular endothelial growth factor mRNA by the product of the VHL tumour suppressor gene. Proc Natl Acad Sci USA 93: 10589–10594
Green D, Meza-Junco J, Arce C et al. (2005) Phase II trial of thalidomide for patients with metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 23: Abstract 4761
Gulley J, Chen AP, Dahut W et al. (2002) Phase I study of a vaccine using recombinant vaccinia virus expressing ps metastatic androgene independent prostate cancer. Prostate 53: 109–117
Hainsworth JD, Sosman JA, Spigel DR et al. (2005) Treatment of metas-tatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 23: 7889–7896
Kaufman HL, Wang W, Manola J et al. (2004) Phase II randomized study of vaccine treatment of advanced prostate cancer (e7897) a coo-perative oncology group study. J Clin Oncol 22: 2122–2132
Kuenen BC, Tabernero J, Baselga J et al. (2003) Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma and soft tissue sarcoma. Clin Cancer Res 9: 1648–1655
Lager DJ, Slagel DD, Palechek PL (1994) The expression of epidermal growth factor receptor and transforming growth factor alpha in renal cell carcinoma. Mod Pathol 7: 544–548
Lattime EC, Weiss RE, Stein MN et al. (2005) Phase I study of intravesical recombinant FOWLPOX-GM-CSF and/ or recombinant FOWLPOX-Tricom in patients with advanced bladder cancer. Proc Am Soc Clin 41: Abstract 4755
Motzer RJ, Amato R, Todd M et al. (2003) Phase II trial of antiepidermal growth factor receptor antibody c225 in patients with advanced renal cell carcinoma Invest New Drugs 21: 99–101
Motzer RJ, Rini BI, Michaelson M et al. (2005) Sunitinib malate (SU11248) shows antitumour activity in patients with metastatic renal cell carcinoma: updated results from phase II trials. Eur J Cancer, Suppl 3: 2: p 227: Abstract 797
Motzer RJ, Dror Michaelson M, Redman BG et al. (2006) Activity of SU11249: a multitargeted inhibitor of vascular endothelial growth facto rand platelet derived growth factor, in patients with metas-tatic renal cell carcinoma. J Clin Oncol 24: 16–24
Mukhopadhyay D, Knebelmann B, Cohen HT et al. (1997) The von Hip-pel-Lindau tumour suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promotor activity. Mol Cell Biol 17: 5629–5639
Picus J, Halabi S, Rini B et al. (2003) The use of bevacizumab with do-cetaxel and estramustine in hormone refractory prostate cancer:initial results of CALGB 90006. Proc Am Soc Clin Oncol 39: Abstract393
Schwartz G, Dutcher JP, Vogelzang NJ et al. (2002) Phase 2 clinical evaluating safety and effectiveness of ABX-EGF in renal cell cancer Proc Am Soc Clin Oncol 39: Abstract 91
Sella A, Sternberg C, Yarom N et al. (2003) Phase II study of low dose thalidomide and interferon-alfa in metastatic renal cell carcinoma Proc Am Soc Clin Oncol s22: Abstract 1614
Small E J, Schellhammer PF, Higano CS et al. (2005) Results of a pla-cebo-controlled phase III trial of immunotherapy with APC8015 for patients with hormone refractory prostate cancer. Proc Am Soc Clin Oncol 24: Abstract 4500
Srivastava PK (2006) Therapeutic cancer vaccines. Curr Opin Immunol 19: 201–205
Yang J C (2004) Bevacizumab for patients with metastatic renal cancer an update. Clin Cancer Res 10: 6367S–6370S
Yang J C, Haworth L, Sherry RM et al. (2003) A randomized trial of beva-cizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427–434
Literatur zu Kap. 6.2
Aapro M (2005) Optimising antiemetic therapy: what are the problems and how can they be overcome? Curr Med Res Opin Jun; 21(6): 885–897
Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol Mar 1; 22(5): 909–918
Barth J, Kloke M (2003) Paravasation bei Zytostatika. In: Seeber S, Schütte J (Hrsg) Therapiekonzepte Onkologie, 4. Aufl. Springer 2003, Berlin Heidelberg New York Tokio, S 1708–1715
Basser RL, Green MD (1994) Pulmonary toxicities. In: Kirkwood JM, Lotze MT, Yasko JM (eds). Current cancer therapeutics. Current Medicine, Philadelphia, pp 272–278
Bellone JD (1981) Treatment of vincristin extravasation. JAMA 245: 343
Billingham ME, Mason GW, Bristow MR et al. (1978) Anthracycline cardiomyopathy monitored by morphological changes. Cancer Treat Pep 62: 865–872
Bokemeyer C, Oechsle K, Hartmann JT, Schoffski P, Schleucher N, Metz-ner B, Schleicher J, Kanz L. (2002) Treatment-induced anaemia and ist potential clinical impact in patients receiving sequential high dose chemotherapy for metastatic testicular cancer. Br J Cancer Nov 4; 87(10): 1066–1071
Bokemeyer C, Schmoll HJ, Polivoda H (1994) Sekundäre Leukämien nach Etoposid-haltiger Chamotherapie. Dtsch Med Wochenschr 119: 707–713
Bowyer GW, Davies TW (1987) Methotrexate toxicity associated with an ileal conduit. Br J Urol 60: 592
Bristow MR, Thompson PD, Martin RP, Mason JW, Billingham ME, Hassison D (1978) Early anthracycline cardiotoxicity. Am J Med 65: 823–832
Bronchud MH, Scarffe JH, Thatcher N (1988) Phase I/II study of recom-binant human granulocyte colonystimulating factor in patients receiving intensive chemotherapy for small cell lung cancer re-combinant human granulocyte-macrophage colonystimulating factor in AIDS (letter). N Eng J Med 318: 579
Bronner A, Hood A (1983) Cutaneous complications of chemothera-peutic agents. J Am Acad Dermatol 9: 646–666
Canon JL (2005) Final Results of a Randomized, Double-Blind, Active-Controlled Trial of Darbepoetin alfa Administered Once Every 3 Weeks (Q3 W) for the Treatment of Anemia in Patients Receiving Multicycle Chemotherapy. Proc. ASCO 2005; 23: 8284
Carmichael DJS (1992) Handling of drugs in kidney disease. In: Came-ron S, Davison AM, Grünfeld JP, Kerr D, Ritz E (eds) Oxford textbook of clinical nephrology. Univ Press Oxford, pp 175–196
Cooper JAD Jr, White DA, Matthay RA (1986) Drug-induced pulmo-nary disease. Part 1: Cytotoxic drugs. Am Rev Respir Dis 133: 321–340
De Wit R, Herrstedt J, Rapoport B, Carides AD, Carides G, Elmer M, Schmidt C, Evans JK, Horgan KJ (2003) Addition of the oral NK1 antagonist aprpitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol Nov 15; 21(22): 4105–11. Epub 2003 Oct 14
Di Lorenzo G, Autorino R, D’Armiento FP, Mignogna C, De Laurentiis M, De Sio M, D’Armiento M, Damiano R, Vecchio G, De Placido S (2004) Expression of proto-oncogene c-kit in high risk prostate cancer. Eur J Surg Oncol NOV; 30(9): 987–92
Di Lorenzo G, Autorino R, De Laurentiis M, Cindolo L, D’Armiento M, Bianco AR, De Placido S (2004) HER-2/neu receptor in prostate cancer development and progression to and rogen independence. Tumori Mar-Apr; 90(2): 163–70
Drasga RE, Einhorn LH, Williams SD, Patel DN, Stevens EE (1983) Fertility after chemotherapy for testicular cancer. J Clin Oncol 1: 179–183
Du XX, Williams DA (1994) Interleukin 11: a multifunctional growth factor derived from the hematopoitic microenvironment. Blood 83: 2023–2030
Fink U, Peters HD, Schmoll HJ (1987) Antiemetische Therapie. In Schmoll H-J, Peter H-D, Fink U (Hrsg) Kompendium internistische Onkolo-gie. Springer, Berlin Heidelberg New York Tokyo, S 317–345
Fossa SD, Ous S, Abyholm T, Norman N, Loeb M (1985) Post-treatment fertility in patients with testicular cancer. II. Influence of cis-platin-based combination chemotherapy and of retroperitoneal surgery on hormone and sperm cell production. Br J Urol 57: 210–214
Fossa SD, Heilo A, Botinger O (1990) Unexpected high serum levels in cystectomiced bladder cancer patients with an ileals conduit treated intermediate doses of the drug. J Urol 143: 498
Gabrilove JL, Jakukowski A, Scher H (1988) Effect of granulocyte col-ony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell-carcinoma of the uro-thelium. N Engl J Med 318: 1414
Gallmeier WM (1979) Zytostatikum para: was tun? Münch Med Wo-chenschr 121: 11
Golde DW (1990) Hämatopoetine gleichen Abwehrschwäche aus. On-col Rev 5/2: 6
Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ; Aprepitant Protocol 052 Study Group (2003) The oral neurokin-1 antagonist aprepitant for the prevention of chemothe-rapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin the Aprepitant Protocol 052 Study Group. J Clin Oncol Nov 15; 21(22): 4112–4119. Epub 2003 Oct 14
Hesketh PJ, Van Belle S, Aapro M, Tattersall FD, Naylor RJ, Hargreaves R, Carides AD, Evans JK, Horgan KJ (2003) Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer May; 39(8): 1074–80
Hofer MD, Fecko A, Shen R, Setlur SR, Pienta KG, Tomlins SA, Chinnaiyan AM, Rubin MA (2004) Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors. Neoplasia Sep-Oct; 6(5): 503–12
Ignoffo RJ, Friedman A (1980) Therapy of local toxicities caused by extra-vasation of cancer chemotherapeutic drugs. Cancer Treat Rev 7: 17
Kaplan RS, Wiernik PH (1982) Neurotoxicity of antineoplastic drugs. Semin Oncol 9: 103–130
Köstering H, Nagel G (1982) Prophylaxe und Therapie von Zystostatika-Hautnekrosen. Onkologie: 3: 317
Krege S. (2003) Chemotherapy of advanced urological tumors. Onkolo-gie Oct; 26Suppl 4: 13–7
Kreisman H, Wolkove N (1992) Pulmonary toxicity of antineiplastic the-rapy. In: Perry MC (ed) The chemotherapy source book. Williams & Wilkins, Baltimore, pp 598–619
Kuderer et.al. (2005) Meta-analysis of prophylactic granulocyte-col-ony-stimulating-factor (G-CSF) in cancer patients receiving che-motherapy. Proc ASCO 2005; 23: #8117 Abstract
La Bianca R, Beratta G, Cleric M et al. (1982) Cardiac toxicity of 5-fluo-rouracil: a study of 1083 patients. Tumori 68: 505–510
Lara PN Jr, Twardowski P, Quinn DI (2004) Angiogenesis-targeted thera-pies in prostate cancer. Clin Prostate Cancer Dec; 3(3): 165–173
Larson DL (1982) Treatment of tissue extravasation by antitumor agents. Cancer 49: 1796
Leyden M, Sullivan J (1983) Full-Sickness skin-necrosis due to inadver-tent interstitiell infusion of cis-platin. Cancer Treal Rep 67: 199
Miller RS, Freiha FS, Torti FM (1991) Surgical restaging of PTS with advan-ced TCC of the urothelium treated with CHV. Proc ASCO 10: 530
National Cancer Institute (NCI) (1993) Investigators handbook. A ma-nual for participants in clinical trials of investigational agents. Can-cer therapy evaluation program. Diversion of cancer treatment. National Cancer Institute, Bethesda/MD
Nichols CR, Breeden ES, Loehrer PJ, Williams SD, Einhorn LH (1993) Secondary leukemia associated with a conventional dose of eto-poside. J Natl Cancer Inst 85: 36–40
Perez CA, Brady LW (1993) Principles and practice of radiation onco-logy, 2nd edn. Lippincott, Philadelphia, pp 51–55
Petersen PM, Hansen SW, Giwercman A, Rorth M, Stakkebaek NE (1994) Dose-dependent impairment of testicular function in patients treated with cisplatin-based chemotherapy for germ cell cancer. Ann Oncol 5: 355–358
Pizzo PA (1984) Granulocytopenia and cancer therapy. cancer 54: 2649
Platzer E (1990) Human haemotopoetic growth factors. Eur J Haematol 42: 1
Pogothesis CJ, Dexeus FH, Sella A, Amato RJ, Kilbourn RG, Finn L, Gutterman JU (1990) Excalated therapy for refractory urothelial tumors: methotrexate-vinblastine-doxorubicin-cisplatin plus un-glycosyleted recombinant human granulocyte macrophage col-ony-stimulating factor. J Natl Cancer Inst 828: 667
Pont J, Albrecht W (1997) Fertility after chemotherapy for testicular germ cell cancer. Fertil Steril 68: 1–5
Rao K, Goodin S, Levitt MJ, Dave N, Shih WJ, Lin Y, Capanna T, Doyle-Lindrud S, Juvidian P, DiPaola RS (2005) A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostata cancer. Prostate 2005 Feb 1; 62(2): 115–22
Rizzo JD, Lichtin AE, Woolf SH (2002) Use of Epoetin in patients with cancer: evidence-based clinical practice guidelines of American Society of Clinical Oncology and the American Society of Hema-tology. J Clin Oncol 20: 1–25, 2002
Roberts JT, Fossa SD, Parmar MKB (1991) Results of medical research council phase II study of low dose cisplatin and methotrexate in the primary treatment of locally advanced transitional cell carci-noma of the bladder. Br J Urol 68: 162
Rosenow III EC, Meyers JL, Swensen SJ, Pisani RJ (1992) s. alte Auflage
Sauer H (2000) In: Wilmanns W, Huhn D, Wilms K (Hrsg) Internistische Onkologie. Thieme, Stuttgart New York
Schaaf D, Schott E (1984) Entsorgung und Vernichtung von Zytostatika-abfällen. Krankenhauspharmazie 5. Jahrgang, Heft 10
Schmoll HJ, Höffken K, Possinger K (1996) Kompendium Internistische Onkologie, Teil 1. 2. Aufl. Springer, Berlin Heidelberg New York Tokio
Sternberg CN, Yagoda A, Scher HI et al. (1986) Surgical staging and long term survival in patients with advanced transitional cell carcinoma (TCC) of the urothelium treated with M-VAC. Proc ASCO 5: 390
Thurber WA (1989) Offspring of childhood cancer survivors. J Assoc Pediatr Oncol Nurses 6: 17–19
Van Sloten Harwood K, Aisner J (1984) Treatment of chemotherapy extravasation: Current status. Cancer Treat Rep 68: 939
Wander HE, Nagel GA (1985) Mammakarzinome, 3. Aufl. Zuckschwerdt, München Bern Wien
Wood AJJ (1998) Drug therapy. N Engl J Med 339: 746–754
World Health Organisation (1979) WHO handbook for reporting results of cancer treatment. World Health Organization Offset Publication No. 48, Geneva, Retrieved July 2004
Literatur zu Kap. 6.3
Aast N, De Mulder PH, Mickisch GH, Mulders P, van Oosterom AT, van Poppel H, Fossa SD, de Prijck L, Sylvester RJ (2005) Randomized phase II/III trial of interferon Alfa2a with and without 13-cis-re-tinoic acid in patients with progressive metastatic renal cell carci-noma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951). J Clin Oncol 23: 4172–4178
Amato RJ (2003) Thalidomide therapy for renal cell carcinoma. Crit Rev Oncol Hematol. 46: S59–S65
Atzpodien J, Kirchner H, Jonas U, Bergmann L, Schott H, Heynemann H, Fornara P, Loening SA, Roigas J, Muller SC, Bodenstein H, Pomer S, Metzner B, Rebmann U, Oberneder R, Siebels M, Wandert T, Puchberger T, Reitz M; Prospectively randomized study of the Ger-man Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN) (2004) Interleukin2-and interferon alfa2a-based immu-nochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German Cooperative Renal Carcinoma Che-moimmunotherapy Group (DGCIN). J Clin Oncol 22: 1188–1194
Atzpodien J, Schmitt E, Gertenbach U, Fornara P, Heynemann H, Mas-kow A, Ecke M, Woltjen HH, Jentsch H, Wieland W, Wandert T, Reitz M; German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group (DGCIN) (2005) Adjuvant treatment with interleukin2-and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Che-moimmunotherapy Group (DGCIN). Br J Cancer 92: 843–846
Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ (2005) Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 23: 4591–4601
Bassi P, Spinadin R, Carando R, Balta G, Pagano F (2000) Modified induction course: a solution to side-effects? Eur Urol 37Suppl1: 31–32
Bleumer I, Knuth A, Oosterwijk E, Hofmann R, Varga Z, Lamers C, Kruit W, Melchior S, Mala C, Ullrich S, De Mulder P, Mulders PF, Beck J (2004) A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer 90: 985–990
Bleumer I, Oosterwijk E, Oosterwijk-Wakka JC, Voller MC, Melchior S, Warnaar SO, Mala C, Beck J, Mulders PF (2006) A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleu-kin2 pulsing scheme for advanced renal cell carcinoma. J Urol 175: 57–62
Burch PA, Croghan GA, Gastineau DA, Jones LA, Kaur JS, Kylstra JW, Richardson RL, Valone FH, Vuk-Pavlovic S (2004) Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a phase 2 trial. Prostate 60: 197–204
Canil CM, Moore MJ, Winquist E, Baetz T, Pollak M, Chi KN, Berry S, Ernst DS, Douglas L, Brundage M, Fisher B, McKenna A, Seymour L (2005) andomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. 23: 455–460
Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Dali-ani DD, Schulman CC, Nabulsi AA, Humerickhouse RA, Weinberg MA, Schmitt JL, Nelson JB (2003) Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hor-mone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 21: 679–689
Clark JI, Atkins MB, Urba WJ, Creech S, Figlin RA, Dutcher JP, Flaherty L, Sosman JA, Logan TF, White R, Weiss GR, Redman BG, Tretter CP, McDermott D, Smith JW, Gordon MS, Margolin KA (2003) Adjuvant high-dose bolus interleukin2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 21: 3133–3140
Colombel M, Saint F, Chopin D, Malavaud B, Nicolas L, Rischmann P (2006) The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, mul-ticenter sstudy. J Urol 176: 935–939
Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T (2005) Immu-notherapy for advanced renal cell cancer. Cochrane Database Syst Rev 25: CD001425
Culy C (2005) Bevacizumab: Antiangogenic cancer therapy. Drugs Today 41: 2–36
Dalgleish AG, Quatan N, Michael A., Wushishi F, Pandha H (2005) Incre-ased time to progression and sustained PSA velocity responses in a Phase II trial in advanced metastatic prostate cancer following treatment with ONY-P1, an allogeneic whole cell vaccine. J Clin Oncol 23(16S): Abs 4726
Den Otter W, Dobrowolski Z, Bugajski A, Papla B, Van Der Meijden AP, Koten JW, Boon TA, Siedlar M, Zembala M (1998) Intravesical inter-leukin2 in T1 papillary bladder carcinoma: regression of marker lesion in 8 of 10 patients. J Urol 159: 1183–1186
Doehn C, Kausch I, Melz S, Behm A, Jocham D (2004a) Cytokine and vaccine therapy of kidney cancer. Exp Rev Anticancer Ther 4: 1097–1111
Doehn C, Jocham D (2004b) Vaccination immunotherapy-an update. Scand J Surg 93: 163–169
Eaton JD, Perry MJ, Nicolson S, Guckian M, Russel N, Whelan M, Kirby RS. Allogeneic whole-cell vaccine: a phase I/II study in men with hormone-refractory prostate cancer. BJU Int 89: 19–26
Elaraj DM, White DE, Steinberg SM, Haworth L, Rosenberg SA, Yang JC (2004) A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma. J Immunother 27: 259–264
Escudier B, Szczylik C, Eisen T, Stadler WM, Schwartz B, Shan M, Bu-kowski RM (2005) Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 439006) in patients with advan-ced renal cell carcinoma (RCC). J Clin Oncol 23(16S): Abs 4510
Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM; TARGET Study Group (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125–134
Ghobrial IM, Rajkumar SV (2003) Management of thalidomide toxicity. J Support Oncol 1: 194–205
Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A (2005) Treatment of metastatic renal cell carcinoma with a combi-nation of bevacizumab and erlotinib. J Clin Oncol 23: 7889–7896
Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staros-lawska E, O’Toole E, Park Y, Moore L (2006) A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). J Clin Oncol Vol 24(18S) 2006: LBA4
Huland E, Huland H (1989) Local continuous high dose interleukin 2: a new therapeutic model for the treatment of advanced bladder carcinoma. Cancer Res 49: 5469–5474
Huland E, Huland H (1992) Tumor-associated eosinophilia in interleu-kin2-treated patients: evidence of toxic eosinophil degranulation on bladder cancer cells. J Cancer Res Clin Oncol 118: 463–467
Huland E, Burger A, Fleischer J, Fornara P, Hatzmann E, Heidenreich A, Heinzer H, Heynemann H, Hoffmann L, Hofmann R, Huland H, Kampfer I, Kindler M, Kirchner H, Mehlhorn G, Moniak TH, Rebmann U, Roigas J, Schneider TH, Schnorr D, Schmitz HJ, Wenisch R, Varga Z, Vinke J (2003) Efficacy and safety of inhaled recombinant interleu-kin2 in high-risk renal cell cancer patients compared with systemic interleukin2: an outcome study. Folia Biol. (Praha) 49: 183–190
Jocham D, Richter A, Hoffmann L, Iwig K, Fahlenkamp D, Zakrzewski G, Schmitt E, Dannenberg T, Lehmacher W, von Wietersheim J, Do-ehn C (2004) Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 363: 594–599
Joudi FN, Smith BJ, O’Donnell MA; National BCG-Interferon Phase 2 Investigator Group (2006) Final results from a national multicen-ter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha2B for reducing recurrence of superficial bladder cancer. Urol Oncol 24: 344–348
Kumar S, Witzig TE, Rajkumar SV (2004) Thalidomide: Current role in the treatment of non-plasma cell maligancies. J Clin Oncol 22: 2477–2388
Lamm DL, van der Meijden PM, Morales A, Brosman SA, Catalona WJ, Herr HW, Soloway MS, Steg A, Debruyne FM (1992) Incidence and treatment of complications of bacillus Calmette-Guerin intravesi-cal therapy in superficial bladder cancer. J Urol 147: 596–600
Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED (2000) Maintenance bacillus Calmette-Guerin immu-notherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163: 1124–1129
Lee CP, Patel PM, Selby PJ, Hancock BW, Mak I, Pyle L, James MG, Beirne DA, Steeds S, A’Hern R, Gore ME, Eisen T (2006) Randomized phase II study comparing thalidomide with medroxyprogesterone ace-tate in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 898–903
Lorenz J, Wilhelm K, Kessler M, Peschel C, Schwulera U, Lissner R, Struff WG, Huland E, Huber C, Aulitzky WE (1996) Phase I trial of inhaled natural interleukin 2 for treatment of pulmonary malignancy: toxicity, pharmacokinetics, and biological effects. Clin Cancer Res 2: 1115–1122
Martinez-Pineiro JA, Martinez-Pineiro L, Solsona E, Rodriguez RH, Go-mez JM, Martin MG, Molina JR, Collado AG, Flores N, Isorna S, Pertusa C, Rabadan M, Astobieta A, Camacho JE, Arribas S, Madero R; Club Urologico Espanol de Tratamiento Oncologico (CUETO) (2005) Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a pros-pective randomized trial. J Urol 174: 1242–1247
Merimsky O, Gez E, Weitzen R, Nehushtan H, Rubinov R, Hayat H, Peretz T, Ben-Shahar M, Biran H, Katsenelson R, Mermershtein V, Loven D, Karminsky N, Neumann A, Matcejevsky D, Inbar M (2004) Targe-ting pulmonary metastases of renal cell carcinoma by inhalation of interleukin2. Ann Oncol 15: 610–612
Messing EM, Manola J, Wilding G, Propert K, Fleischmann J, Crawford ED, Pontes JE, Hahn R, Trump D (2003) Eastern Cooperative On-cology Group/Intergroup trial (2003) Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 21: 1214–1222
Michael A, Ball G, Quatan N, Wushishi F, Russell N, Whelan J, Chakra-borty P, Leader D, Whelan M, Pandha H (2005) Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin Cancer Res 11: 4469–4478
Motzer RJ, Murphy BA, Bacik J, Schwartz LH, Nanus DM, Mariani T, Loehrer P, Wilding G, Fairclough DL, Cella D, Mazumdar M (2000) Phase III trial of interferon alfa2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 18: 2972–2980
Motzer RJ, Berg W, Ginsberg M, Russo P, Vuky J, Yu R, Bacik J, Mazumdar M (2002) Phase II trial of thalidomide for patients with advanced renal carcinoma. J Clin Oncol 20: 302–306
Motzer RJ, Amato R, Todd M, Hwu WJ, Cohen R, Baselga J, Muss H, Cooper M, Yu R, Ginsberg MS, Needle M (2003) Phase II trial of an-tiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 21: 99–101
Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI (2006a) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and pla-telet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 16–24
Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Red-man BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD (2006b) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295: 2516–2524
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115–124
Nanus DM, Milowsky MI, Kostakoglu L, Smith-Jones PM, Vallabahajo-sula S, Goldsmith SJ, Bander NH (2003) Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J Urol 170: S84–S88
Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ra-vaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T (1998) Recombinant human interleukin2, recombinant human interfe-ron alfa2a, or both in metastatic renal-cell carcinoma. Groupe Francais dImmunotherapie. N Engl J Med 338: 1272–1278
Negrier S, Caty A, Lesimple T, Douillard J-Y, Escudier B, Rossi J-F, Viens P, Gomez F (2000) Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin2 and interferon alfa with or without fluorouracil. J Clin Oncol 18: 4009–4015
O’Donnell MA, Lilli K, Leopold C; National Bacillus Calmette-Gue-rin/Interferon Phase 2 Investigator Group (2004) Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer. J Urol 172: 888–893
Olencki T, Malhi S, Mekhail T, Dreicer R, Elson P, Wood L, Bukowski RM (2006) Phase I trial of thalidomide and Interleukin2 in patients with metastatic renal cell carcinoma. Invest New Drugs, published online: 28 January 2006.
Papatsoris AG, Deliveliotis C, Giannopoulos A, Dimopoulos C (2004) Adjuvant intravesical mitoxantrone versus recombinant interfe-ron-alpha after transurethral resection of superficial bladder can-cer: a randomized prospective study. Urol Int 72: 284–291
Pizza G, Severini G, Menniti D, De Vinci C, Corrado F (1994) Tumour regression after intralesional injection of interleukin 2 (IL2) in bladder cancer. Preliminary report. Int J Cancer 34: 359–367
Pizzocaro G, Piva L, Colavita M, Ferri S, Artusi R, Boracchi P, Parmiani G, Marubini E (2001) Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric rando-mized study. J Clin Oncol 19: 425–431
Ragde H, Cavanagh WA, Tjoa BA (2004) Dendritic cell based vaccines: progress in immunotherapy studies for prostate cancer. J Urol 172: 2532–2538
Rajala P, Kaasinen E, Raitanen M, Linkonen T, Rintala E (2002) Finnblad-der Group. Perioperative single dose instillation of epirubicin or interferon alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomised multicenter study-FinnBladder long-term results. J Urol 168: 981–985
Rao K, Goodin S, Levitt MJ, Dave N, Shih WJ, Lin Y, Capanna T, Doyle-Lindrud S, Juvidian P, DiPaola RS (2005) A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer. Prostate 62: 115–122
Rowinsky EK, Schwartz GH, Gollob JA, Thompson JA, Vogelzang NJ, Figlin R, Bukowski R, Haas N, Lockbaum P, Li YP, Arends R, Foon KA, Schwab G, Dutcher J (2004) Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 22: 3003–3015
Seegenschmidt MH, Müller RP, Höffken K, Junginger T, Sauer H (1999) Dokumentation von Nebenwirkungen in der Onkologie. Dtsch ärztebl 96: A489–A495
Shelley MD, Court JB, Kynaston H, Wilt TJ, Coles B, Mason M (2003) In-travesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database Syst Rev 3: CD003231
Schenkman E, Lamm DL (2004) Superficial bladder cancer therapy. Scientific World Journal 28(4Suppl 1): 387–399
Simons J, Nelson W, Nemunaitis J, Centeno A, Dula E, Urba W, Smith D, Marshall F, Howard C, Ando D, Small E (2002) Phase II trials of a GM-CSF gene-transduced prostate cancer cell line vaccine (GVAX) in hormone refractory prostate cancer. Proc Am Soc Clin Oncol; 21(Pt 1): 183a (Abs 729)
Simons JW, Higano C, Smith D, Corman J, Steidle C, Gittelman M, Hu-des G, Aimi J, Sacks N, Small E (2005) Clinical and immunologic findings in a phase 2 study of a GM-CSF-secreting prostate cancer cell line vaccine in patients with metastatic hormone-refractory prostate cancer (met HPRC). J Clin Onco 23(16S): Abs 2517
Simons JW, Small E, Nelson W, Nemunaitis J, Centeno A, Dula E, Urba W, Smith D, Marshall F, Borellini F, Sy J, Marshall M (2001) Phase II trials of a GM-CSF gene-transduced prostate cancer cell line vaccine (GVAX) demonstrate anti-tumor activity. Proc Am Soc Clin Oncol 20(Pt 1): 269a (Abs 1073).
Small E, Higano C, Smith D, Corman J, Centeno A, Steidle C, Gittelman M, Hudes G, Sacks N, Simons J (2004) A phase 2 study of an allo-geneic GM-CSF gene-transduced prostate cancer cell line vaccine in patients with metastatic hormone-refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 22(14S): Abs 4565
Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM (2006) Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24: 3089–3094
Swindle PW, Tepes S, Clements J (2004) DC therapy for prostate cancer. Cytotherapy 6: 164–171
Varga Z, de Mulder P, Kruit W, Hegele A, Hofmann R, Lamers C, Warnaar S, Mala C, Ullrich S, Mulders P (2003) A prospective open-label single-arm phase II study of chimeric monoclonal antibody cG250 in advanced renal cell carcinoma patients. Folia Biol (Praha) 49: 74–77
Weiss GR, O’Donnell MA, Loughlin K, Zonno K, Laliberte RJ, Sherman ML (2003) Phase 1 study of the intravesical administration of recombinant human interleukin12 in patients with recurrent su-perficial transitional cell carcinoma of the bladder J Immunother 26: 343–348
Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, Seipp CA, Rogers-Freezer L, Morton KE, White DE, Liewehr DJ, Merino MJ, Rosenberg SA (2003a) Randomized study of high-dose and low-dose interleukin2 in patients with metastatic renal cancer. J Clin Oncol 21: 3127–3132
Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA (2003b) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427–434
Ziada A, Barqawi A, Glode LM, Varella-Garcia M, Crighton F, Majeski S, Rosenblum M, Kane M, Chen L, Crawford ED (2004) The use of tras-tuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 60: 332–337 http://www.ctep.cancer.gov http://www.fda.gov/cder/cancer/toxicityframe.htm
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
Doehn, C. et al. (2007). Grundlagen der systemischen Therapie. In: Rübben, H. (eds) Uroonkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-33848-2_6
Download citation
DOI: https://doi.org/10.1007/978-3-540-33848-2_6
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-33847-5
Online ISBN: 978-3-540-33848-2
eBook Packages: Medicine (German Language)